MedPacto Obtains European Patent for Composition Related to Blood Cancer Prevention and Treatment
[Asia Economy Reporter Kum Boryeong] MedPacto announced on the 1st that it has obtained a European patent related to 'a novel pyrimidine compound, a method for its manufacture, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of cancer and inflammatory diseases.'
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
MedPacto stated, "We are currently developing MU-D201, a low-molecular anticancer new drug, for the treatment of diffuse large B-cell lymphoma, γδT cell acute lymphoblastic leukemia, and other conditions," adding, "This patent will be utilized to protect intellectual property rights and enhance value during future research and development of MU-D201 and technology transfer negotiations with global pharmaceutical companies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
